We’ve all had a moment where we arrived at the grocery store and can’t remember passing any of the stoplights along the way. We’re halfway down an aisle and scrambling to remember what we even needed. Our mind is in overdrive trying to sort through our ever-growing to-do list. We’ve been there when just making it through the next task is hard. But the normal stresses of life aren’t the only thing YOU have to deal with. Nora McInerny hosts The Head Start: Embracing the Journey, a new podcast ...
…
continue reading
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
HCPLive Under 5 Audio Recap: Week of 05/04
MP3•Episode home
Manage episode 482085450 series 3310601
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 28-May 4, 2025:
Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials
Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025.
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial
MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy.
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial
Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option.
UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks
UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study.
Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients
Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 28-May 4, 2025:
Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials
Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025.
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial
MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy.
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial
Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option.
UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks
UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study.
Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients
Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.
190 episodes
MP3•Episode home
Manage episode 482085450 series 3310601
Content provided by HCPLive Podcasts. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by HCPLive Podcasts or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let’s dive into the latest updates impacting clinicians and healthcare providers like you!
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 28-May 4, 2025:
Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials
Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025.
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial
MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy.
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial
Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option.
UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks
UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study.
Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients
Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for April 28-May 4, 2025:
Obicetrapib Achieves Robust LDL-C Reductions in Phase 3 ASCVD Trials
Obicetrapib significantly reduced LDL-C as monotherapy and in combination with ezetimibe in ASCVD patients inadequately controlled by statins, according to Phase 3 data presented at EAS 2025.
MAR001 Cuts Remnant Cholesterol, Triglycerides by 50% in Phase 2a Trial
MAR001, a novel ANGPTL4-targeting monoclonal antibody, reduced remnant cholesterol and triglycerides by over 50% in high-risk patients, suggesting a promising new cardiovascular intervention strategy.
Oral Zervimesine Reduces Geographic Atrophy Lesion Growth in Phase 2 Trial
Zervimesine (CT1812) slowed lesion progression in geographic atrophy secondary to AMD in Phase 2 MAGNIFY trial results, offering a potential oral treatment option.
UBX1325 Matches Aflibercept in Vision Gains for DME at 36 Weeks
UBX1325 demonstrated noninferiority to aflibercept in visual acuity gains in patients with diabetic macular edema over 36 weeks in the Phase 2b ASPIRE study.
Roflumilast Foam 0.3% for Scalp, Body Psoriasis Effective, Safe for Patients
Roflumilast foam 0.3% achieved significant efficacy and rapid symptom control in scalp and body psoriasis, with an FDA decision expected by late May 2025.
190 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.